EAU 2021: Clinical Benefit and Safety Profile of Darolutamide in Patients Who Crossed over to Darolutamide from Placebo During the Open-Label Period of the Phase 3 ARAMIS Study

(UroToday.com) Darolutamide (DARO) is a structurally distinct androgen receptor inhibitor (ARI) that has been demonstrated to significantly prolong metastasis-free survival and overall survival in the ARAMIS trial.¹